

COMPOUNDED DRUG TESTING REPORT Fiscal Year 2006

In 2003 the Board initiated a program to test drug preparations compounded by pharmacies. All preparations are tested for potency and, if applicable, sterility and endotoxin. The tables below are for the fiscal year ending 6/30/06.

Dosage Form	Tests Performed
Capsule	63
I.V. solution	11
Inhalation solution	4
Injectable solution	9
Oral solution/suspension	161
Suppository	9
Tablet	1
Topical cream/ointment/liquid	3
TPN solution	1
Transdermal	12

Test Results	Tests Performed	Percentage
Satisfactory	205	74.8%
Unsatisfactory	69	25.2%
Total	274	100%

All unsatisfactory results were related to potency failures. An acceptable potency range is considered +/- 10% of the expected potency, unless a U.S.P. monograph states a different range for a specific preparation. Failing potency results ranged from 0.0% to 259.0%.

Drugs with unsatisfactory results
Alprostadi/Phentolamine/Papaverine
Amlodipine
Azathioprine
Baclofen
Bi-Est/Pregnenolone/Progesterone

Bi-Est/Progesterone
Bi-Est/Progesterone/Testosterone
Bi-Est/Progesterone/Testosterone/DHEA
Budesonide
Captopril
Clindamycin/Hydrocortisone
Clonazepam
Clonidine
Enalapril
Estradiol/Estriol
Estradiol/Estrone/Estriol
Hypertonic Saline
Ibuprofen
Lansoprazole
Liothyronine
Lorazepam/Diphenhydramine/Haloperidol
Magic Mouthwash
Methimazole
Metronidazole
Omeprazole
Phenytoin
Progesterone/Melatonin/Hydroxytryptophan
Prolox
Promethazine
Rifampin
Spirolactone
Spirolactone/Hydrochlorothiazide
Testosterone
Tri-Est/DHEA
Tri-Est/Progesterone/Testosterone
Tri-Est/Progesterone/Testosterone/DHEA
Vancomycin

Pharmacies are notified of unsatisfactory results and asked to complete a quality assurance review of their compounding practices and provide a corrective action plan.